Navigation Links
Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma
Date:1/17/2008

lly in patients with DBCL are also encouraging".

About ZEVALIN(R)

ZEVALIN(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated for the treatment of patients with relapsed or refractory low-grade or follicular B-cell NHL, including patients with Rituximab-refractory NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab infusions. Yttrium-90 ZEVALIN administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the ZEVALIN therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to ZEVALIN therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). ZEVALIN should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.

Patients and healthcare professionals can visit http://www.zevalin.com for more information.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results.
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
2. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
3. Genasense(R) Can be Administered by Brief High-Dose IV Infusion
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
7. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
8. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
9. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... HANOVER, N.J. , April 24, 2015  Novartis Pharmaceuticals ... for the second year in a row on the annual ... results of its 2015 Top 50 Companies for Diversity on ... York, NY . NPC also ranked second on the ... the Top 10 Companies for Employee Resource Groups list. ...
(Date:4/24/2015)... T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"), a ... products and a licensed producer ("LP") to cultivate marijuana ... Canada ) ("MMPR"), is pleased to announce that ... the transaction announced on March 11, 2015 with Medna ... a total of 20,156,790 common shares of T-Bird (45% ...
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ... Drug Administration (FDA) has accepted its New Drug Application ... interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir ... treatment of adults with chronic genotype 4 (GT4) hepatitis ... the first all-oral, interferon-free therapy being evaluated by the ...
Breaking Medicine Technology:Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 2Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 3Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 4T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
(Date:4/25/2015)... 25, 2015 For thirteen years, the Twin ... protection education event in the nation! This year, on May ... Group, US to take DI Day on the road by ... Davidson, CLU, ChFC, RHU, DIA, CLTC, Chief Executive Officer at ... reflects on the change by stating, "The first Twin Cities ...
(Date:4/24/2015)... New York, NY (PRWEB) April 24, 2015 ... upscale sober living residence in Westchester County. Just 35 ... to help transition individuals back into everyday life while ... for Thursday, May 7, 2015, will allow therapists, doctors ... living areas and learn more about the opportunities offered ...
(Date:4/24/2015)... As the nation recognizes the Month of the ... young men and women, the “Alaska – Forget Me ... presents a special training session on Adverse Childhood Experiences ... understanding of the effect of childhood trauma and, in ... and military – who provide services and support to ...
(Date:4/24/2015)... April 24, 2015 Carvers' goal ... have a successful biking day in Breck. , ... five minutes walking distance from Breckenridge, this family-owned ... in both Breckenridge bike rentals ( http://www.breckenridgeskishop.com/en/rent-equipment ) ... offer extensive bike rentals in May 2015. With ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Lipitor ... forward in the federal multidistrict litigation underway in ... to court documents, the parties involved in the ... 16th detailing, among other things, preparation for the ... counsel for both plaintiffs and defendants have conducted ...
Breaking Medicine News(10 mins):Health News:Secura Consultants Takes DI Day On The Road 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Carvers Breckenridge Bike Rentals Offers Demo Mountain, Tandem, Bike Path Cruiser & JR. Bikes in May 2015 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3
... Silicone breast implants went through a long period of relative dormancy ... Now, two years after the U.S. Food and Drug Administration approved ... plastic surgeon Richard L. Zeff, MD comments on why he feels ... ...
... Corticon offers special pricing on patent-pending Dialogs, the premier platform ... ... Redwood City, CA (PRWEB) April 2, ... in model-driven Business Rules Management Systems (BRMS), today announced special ...
... Nurse Training, Inc., provider of nurse training seminars on DVD and online ... ... April 2, 2009 -- Medical Nurse Training, Inc., provider of nurse training ... its website., , ,Medical Nurse Training, Inc. provides DVD and online courses ...
... IT, a national provider of medical documentation services and software, announced ... innovative medical documentation company that serves more than 450 healthcare professionals ... ... (PRWEB) April 2, 2009 -- MD IT , a national ...
... pregnancy, such as morning sickness, fatigue and weight gain, but despite this, ... Gurgle, we offer a guide to women in their early stages of ... ... (PRWEB) April 2, 2009 -- Around half of all women will experience ...
... April 2 In the first,quarter of 2009 (December ... figure of EUR237.3m (Q1 2008: EUR239.1m) almost at the ... world economy. In,the core business, however, sales by the ... The operating result (adjusted EBITDA) ...
Cached Medicine News:Health News:New Hampshire Cosmetic Plastic Surgeon Discusses Silicone Breast Implants after Breast Augmentation becomes No. 1 Cosmetic Surgery Procedure 2Health News:New Hampshire Cosmetic Plastic Surgeon Discusses Silicone Breast Implants after Breast Augmentation becomes No. 1 Cosmetic Surgery Procedure 3Health News:New Hampshire Cosmetic Plastic Surgeon Discusses Silicone Breast Implants after Breast Augmentation becomes No. 1 Cosmetic Surgery Procedure 4Health News:Corticon Shows Business Transformation Potential of Dialogs, The First Intelligent Interactions Platform, at April 23 Webinar 2Health News:Corticon Shows Business Transformation Potential of Dialogs, The First Intelligent Interactions Platform, at April 23 Webinar 3Health News:Medical Nurse Training, Inc. Announces the Launch of Medicalnursetraining.com 2Health News:MD IT Expands in the Northwest with Acquisition of Seattle's Pro Scribe 2Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 2Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 3Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 4Health News:Gurgle's Guide on How to Beat Morning Sickness and Pregnancy Fatigue 5Health News:Gerresheimer Achieves Solid Growth in Core Markets - Outlook Confirmed 2Health News:Gerresheimer Achieves Solid Growth in Core Markets - Outlook Confirmed 3Health News:Gerresheimer Achieves Solid Growth in Core Markets - Outlook Confirmed 4
Adjustable speed vortex with inter-changeable heads , 110 V...
Adjustable speed vortex with inter-changeable heads, 110 V...
... the Mo Bio Vortex Adapter in conjunction with ... procedures. Using the Mo Bio Vortex Adapter ... and Fast Prep machines which offer the same ... ml) centrifuge tubes at one time and will ...
... Vacuum Controller V-800 and water-cooled secondary condenser ... Compact Housing Model V-500 is a ... most vacuum applications. Applications Ideally ... evaporators Laboratory vacuum source for instruments ...
Medicine Products: